GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » E10

Sangamo Therapeutics (Sangamo Therapeutics) E10 : $-1.09 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Sangamo Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Sangamo Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.270. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.09 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -13.20% per year. During the past 5 years, the average E10 Growth Rate was -10.70% per year. During the past 10 years, the average E10 Growth Rate was -6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Sangamo Therapeutics was 9.30% per year. The lowest was -13.20% per year. And the median was -3.50% per year.

As of today (2024-06-07), Sangamo Therapeutics's current stock price is $0.5743. Sangamo Therapeutics's E10 for the quarter that ended in Mar. 2024 was $-1.09. Sangamo Therapeutics's Shiller PE Ratio of today is .


Sangamo Therapeutics E10 Historical Data

The historical data trend for Sangamo Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics E10 Chart

Sangamo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.69 -0.73 -0.82 -0.94 -1.06

Sangamo Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.93 -0.99 -1.05 -1.06 -1.09

Competitive Comparison of Sangamo Therapeutics's E10

For the Biotechnology subindustry, Sangamo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangamo Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's Shiller PE Ratio falls into.



Sangamo Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sangamo Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.27/131.7762*131.7762
=-0.270

Current CPI (Mar. 2024) = 131.7762.

Sangamo Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -0.100 100.560 -0.131
201409 -0.110 100.428 -0.144
201412 -0.060 99.070 -0.080
201503 -0.080 99.621 -0.106
201506 -0.170 100.684 -0.222
201509 -0.130 100.392 -0.171
201512 -0.200 99.792 -0.264
201603 -0.230 100.470 -0.302
201606 -0.380 101.688 -0.492
201609 -0.270 101.861 -0.349
201612 -0.140 101.863 -0.181
201703 -0.230 102.862 -0.295
201706 -0.170 103.349 -0.217
201709 -0.150 104.136 -0.190
201712 -0.150 104.011 -0.190
201803 -0.230 105.290 -0.288
201806 -0.170 106.317 -0.211
201809 -0.130 106.507 -0.161
201812 -0.180 105.998 -0.224
201903 -0.410 107.251 -0.504
201906 -0.260 108.070 -0.317
201909 -0.240 108.329 -0.292
201912 0.040 108.420 0.049
202003 -0.370 108.902 -0.448
202006 -0.260 108.767 -0.315
202009 -0.010 109.815 -0.012
202012 -0.290 109.897 -0.348
202103 -0.320 111.754 -0.377
202106 -0.330 114.631 -0.379
202109 -0.330 115.734 -0.376
202112 -0.260 117.630 -0.291
202203 -0.300 121.301 -0.326
202206 -0.290 125.017 -0.306
202209 -0.340 125.227 -0.358
202212 -0.320 125.222 -0.337
202303 0.120 127.348 0.124
202306 -0.660 128.729 -0.676
202309 -0.590 129.860 -0.599
202312 -0.340 129.419 -0.346
202403 -0.270 131.776 -0.270

Add all the adjusted EPS together and divide 10 will get our e10.


Sangamo Therapeutics  (NAS:SGMO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Sangamo Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangamo Therapeutics (Sangamo Therapeutics) Business Description

Traded in Other Exchanges
Address
7000 Marina Boulevard, Brisbane, CA, USA, 94005
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Executives
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney director C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow officer: SVP-Chief Development Officer C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker director
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby officer: SVP, Gen. Counsel & Secretary 7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb officer: EVP & General Counsel 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot officer: SVP, Chief Scientific Officer 7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott officer: SVP, Head of Development 7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier officer: EVP, Technical Operations 7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung officer: EVP Chief Business Officer 7000 MARINA BLVD, BRISBANE CA 94005

Sangamo Therapeutics (Sangamo Therapeutics) Headlines

From GuruFocus